Close Menu

NEW YORK (GenomeWeb) – Luminex said today that it has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio for $75 million in combined purchases of stock, assets, and inventory.

The newly acquired flow cytometry portfolio includes Amnis imaging flow cytometry products for cell-based analysis and the Guava portfolio of products, which leverage microcapillary technology and are also used for cell-based analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.